Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MLL1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
MLL1 siRNA is a small interfering RNA designed to silence the expression of the MLL1 (Myeloid/Lymphoid or Mixed-Lineage Leukemia 1) gene, also known as KMT2A. MLL1 is a histone lysine methyltransferase that catalyzes the trimethylation of histone H3 lysine 4 (H3K4me3), an epigenetic modification associated with active gene transcription. In the context of rheumatoid arthritis (RA), MLL1 is aberrantly expressed in synovial fibroblasts (RASFs). Experimental depletion of MLL1 using siRNA has been shown to significantly decrease the mRNA levels of pro-inflammatory cytokines (such as IL-6 and IL-15) and chemokines (including CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1) by reducing H3K4me3 levels at their respective gene promoters. This mechanism suggests that targeting MLL1 may offer a novel epigenetic therapeutic approach for managing chronic inflammatory and destructive joint diseases.
- Other names
- MLL1 small interfering RNAMLL-1 small interfering RNAMLL 1 small interfering RNAKMT2A siRNAKMT-2A siRNAKMT 2A siRNAsiRNA-mediated depletion of MLL1
02
Targets
KMT2AInnate immune RNA sensors
Beyond the preview
Go deeper on MLL1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MLL1 siRNA.